Ipamorelin
Mechanism
Research
Stacks
Protocol
Safety
References
Research & Education Only — This guide is intended for educational and research reference purposes only. It does not constitute medical advice, a treatment recommendation, or a dosing protocol. Peptides listed are research compounds not approved for human therapeutic use unless otherwise specified. Always consult a qualified healthcare professional before making changes to any health or supplementation programme. No Nonsense Fitness is an information resource, not a medical provider.

TL;DR

Ipamorelin nudges the pituitary into releasing your own growth hormone, and the main research finding is that it does this without the cortisol and appetite spikes older GH-releasing peptides cause. That selectivity is backed by animal and early human data. There is also a genuinely separate human RCT thread on it speeding up gut recovery after bowel surgery, which is a different use case entirely from bodybuilding. As always, no doses are published here, and personal use notes on this page are one person's experience, not a protocol.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide belonging to the class of Growth Hormone Releasing Peptides (GHRPs). It functions as a selective agonist of the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHS-R1a). Research into Ipamorelin primarily focuses on its capacity to stimulate the pituitary gland to secrete endogenous growth hormone (GH) without significantly impacting other hormones such as cortisol, prolactin, or adrenocorticotropic hormone (ACTH), a characteristic that differentiates it from some other GHRPs. The compound is investigated across various experimental models for its potential in modulating growth hormone levels, which are implicated in numerous physiological processes including tissue repair, metabolism, and body composition. Scientists are exploring Ipamorelin's specific mechanisms and its unique secretagogue profile compared to other GHRPs. This guide is for educational and research purposes only. Not medical advice.

How strong is the evidence?

Evidence Type Status
Human RCT
Observational
Animal Studies
In Vitro
Regulatory Approval

How does Ipamorelin work?

Ipamorelin exerts its physiological effects by acting as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor. These receptors are densely distributed in the anterior pituitary gland and in the hypothalamus, as well as in peripheral tissues. Upon binding to GHS-R1a, Ipamorelin initiates a cascade of intracellular events that culminates in the stimulation of growth hormone (GH) release from somatotroph cells in the pituitary. Unlike some other GHRPs, Ipamorelin demonstrates a high degree of selectivity for GH release. It has been observed in research models that Ipamorelin can induce a significant increase in circulating GH levels while exhibiting minimal to no impact on the secretion of cortisol, prolactin, or ACTH. This specificity is a key area of investigation, suggesting that Ipamorelin may offer a more targeted approach to modulating GH levels in research contexts by avoiding potential side effects associated with elevated levels of these other hormones.

What has Ipamorelin been studied for?

Growth Hormone Secretion Modulation

Research indicates that Ipamorelin effectively stimulates the pituitary gland to secrete endogenous growth hormone. Studies in animal models and early human trials have consistently shown dose-dependent increases in plasma GH levels following Ipamorelin administration. This effect is observed without a significant rise in other pituitary hormones like ACTH, prolactin, or cortisol, suggesting a unique selectivity amongst ghrelin mimetics.

Body Composition and Muscle Development

Due to its ability to support growth hormone secretion, Ipamorelin has been investigated in animal models for its potential influence on body composition. Studies have explored its role in modulating muscle protein synthesis and fat metabolism, indirectly mediated by increased GH and subsequent IGF-1 levels. Research suggests an association with increased lean body mass and decreased adipose tissue in specific experimental settings.

Bone Density Research

The impact of Ipamorelin on bone metabolism has been explored in various preclinical studies. Given that growth hormone and insulin-like growth factor-1 (IGF-1) play crucial roles in bone formation and remodeling, researchers have investigated whether Ipamorelin-induced GH secretion could contribute to enhanced bone mineral density or support bone repair processes in animal models.

Gastrointestinal Motility Research

As a ghrelin receptor agonist, Ipamorelin's effects extend beyond GH release, with some research focusing on its potential influence on gastrointestinal function. Early human clinical trials investigated Ipamorelin's role in postoperative ileus, a condition characterized by delayed gut motility after surgery. These studies aimed to assess whether Ipamorelin could accelerate gastric emptying and restore normal bowel function.

Sleep and Circadian GH Release

Endogenous growth hormone is released in a pulsatile pattern that follows the sleep-wake cycle, with the largest natural pulses occurring during deep, slow-wave sleep. Because Ipamorelin's secretagogue action depends on stimulating the pituitary's own GH release rather than replacing it, research interest has focused on whether administration timed around the sleep window amplifies this naturally-occurring nocturnal pulse rather than working against it. Direct human sleep-study data isolating this timing effect for Ipamorelin specifically remains limited.

What did the studies actually find?

Study / Model Reported Effect
Rat Pituitary Cells (In vitro) Potent GH release with an EC50 of approximately 1.3 nM, demonstrating high specificity.
Healthy Human Volunteers (Phase II study) Dose-dependent increases in GH Area Under Curve (AUC) by up to 13-fold compared to placebo.
Animal Model (muscle wasting) Observed reduction in muscle protein breakdown markers and improved nitrogen balance.
Human Clinical Trials (postoperative ileus) Demonstrated acceleration of gastric emptying time by approximately 23% compared to placebo in some patient populations.
Rat Model (bone healing) Increased IGF-1 levels and improved bone mechanical strength parameters in fracture repair models.

What has Ipamorelin been studied alongside?

  • Ipamorelin + CJC-1295 (without DAC) → Research rationale: Investigated for synergistic stimulation of GH release by combining a ghrelin mimetic (Ipamorelin) with a Growth Hormone Releasing Hormone (GHRH) analog (CJC-1295 without DAC), targeting different pathways for pulsatile GH secretion.
  • Ipamorelin + CJC-1295 (with DAC) → Research rationale: Explored for prolonged GH elevation, where Ipamorelin provides acute pulsatile release while CJC-1295 (with DAC) offers sustained GHRH agonism due to its extended half-life, aiming for a more continuous GH secretagogue effect.
  • Ipamorelin + Tesamorelin → Research rationale: Studied for combined effects of a GHS-R agonist and a GHRH analog (Tesamorelin is a synthetic GHRH), potentially maximizing endogenous GH production for research into lipolysis and metabolic regulation.
  • Ipamorelin + Growth Factors (e.g., IGF-1 analogs) → Research rationale: Investigated for potential additive or synergistic effects on tissue regeneration and anabolic processes in specific cellular or animal models, by directly providing downstream effectors of GH alongside its secretagogue action.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

I have used Ipamorelin. Here is what that is worth.

Personal experience, not guidance. I have used Ipamorelin, alongside a CJC-type peptide. The amount, the frequency and how long for are not going on this page. Those are between me and the doctor who reads my bloods, and printed here they would stop being my experience and become somebody else's plan.

What transfers is what I judged it on. Bloodwork, in this order: HDL first, then LDL and ApoB, triglycerides, haematocrit, blood pressure, liver, glucose and kidney markers. Then sleep, gym performance, waist, photos, and weekly bodyweight averages rather than any single weigh-in. HDL matters most to me and it is not academic: it dropped during a heavy phase and came back into the normal range later, and nothing about how I felt told me either of those things was happening. That is the whole argument for testing instead of going on feel.

What I would actually say if someone asked whether it was worth it: I went from over 90kg to 72kg with a calorie deficit, enough protein, a four-day resistance split and 10,000 steps a day. I paid a personal trainer thousands to learn that. Nothing I have added since has done a fraction of what those did. Every compound gets the same question from me and most of them fail it: does this genuinely improve the result enough to justify the health cost, the financial cost, the complexity and the uncertainty?

Why there are no doses on this page

This site does not publish doses, durations or frequencies for any compound. Published research protocols for this compound vary considerably between studies in design, intensity and duration. Those details are not something to copy from a fitness website — anyone researching this compound should read the primary literature directly and talk to a doctor who knows their bloods.

What side effects were reported?

  • Transient headaches
  • Flushing sensation
  • Increased appetite (mild to moderate)
  • Dizziness
  • Injection site reactions (e.g., redness, soreness)

No severe adverse events consistently reported in available peer-reviewed literature for Ipamorelin in the context of controlled research settings.

Ipamorelin at a glance

CAS Number
170851-70-4
Molecular Formula
C38H49N9O5
Molecular Weight
711.9 g/mol
Half-Life
Approximately 2 hours (in vivo, varies by model and route)
Synonyms
NNC 26-0161 (PubChem CID 9831659)
Research Classification
Growth Hormone Releasing Peptide (GHRP), Ghrelin Receptor Agonist

The research this page cites

  • Raun K et al. 1998 — Ipamorelin, the first selective growth hormone secretagogue. — European Journal of Endocrinology — [Animal / In vitro]
  • Johansen PB et al. 1999 — Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. — Growth Hormone & IGF Research — [Animal]
  • Andersen NB et al. 2001 — The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. — Growth Hormone & IGF Research — [Animal]
  • Venkova K et al. 2009 — Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. — Journal of Pharmacology and Experimental Therapeutics — [Animal]
  • Beck DE et al. 2014 — Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. — International Journal of Colorectal Disease — [Human RCT]

Frequently Asked Questions

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide in the growth hormone releasing peptide (GHRP) class. It works as a selective agonist at the ghrelin receptor (GHS-R1a), which stimulates the pituitary gland to release the body's own growth hormone.

Is Ipamorelin legal to buy in Ireland?

Ipamorelin is not approved as a medicine by Ireland's Health Products Regulatory Authority (HPRA), the EMA or the FDA. It can be sourced from research peptide suppliers for laboratory and research purposes only, and this guide does not recommend or endorse human use.

How is Ipamorelin different from older GHRPs like GHRP-6 or Hexarelin?

The main research finding that sets Ipamorelin apart is selectivity. Published studies report that it stimulates GH release from the pituitary without meaningfully raising cortisol, prolactin or ACTH, effects that older GHRPs such as GHRP-6 and Hexarelin are reported to produce.

What does the research say about Ipamorelin and body composition?

Animal model research has explored Ipamorelin's indirect effect on body composition, mediated through GH and downstream IGF-1 signalling, with some studies reporting associations with increased lean mass and reduced adipose tissue in specific experimental settings. This is preclinical evidence, not an approved human indication.

Regulatory Note (Ireland): The Health Products Regulatory Authority (HPRA) governs medicinal products in Ireland. Research peptides are not licensed as medicines unless specifically approved. This content is provided under educational and research exemptions. Nothing on this page constitutes a product claim or therapeutic recommendation.

Research Tools — Free to Use

Reconstitution calculator, dosing-frequency planner and cycle-length calculator. No signup required.

Open the Peptide Calculators

Tracking food too? Free calorie counter with barcode scanner →